Pitavastatin: A distinctive lipid-lowering drug

Clinical Lipidology

Volumn 5, Issue 3, 2010, Pages 309-323

  Ose, Leiv ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

cardiovascularb disease; dyslipidemia; hydroxymethylglutaryl coA reductase inhibitor; pitavastatin; primary hypercholesterolemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; DIGOXIN; EZETIMIBE; FENOFIBRATE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ITRACONAZOLE; LACTONE; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CREATINE KINASE BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; ELECTROCARDIOGRAM; EVENING DOSAGE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAPE JUICE; HUMAN; HYPERCHOLESTEROLEMIA; LABORATORY TEST; MYALGIA; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REPRODUCIBILITY; REVIEW; RHABDOMYOLYSIS; RHINOPHARYNGITIS; RISK FACTOR; SIDE EFFECT; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; VITAL SIGN;

EID: 77953819724     PISSN: 17460875     EISSN: None     Source Type: Journal    
DOI: 10.2217/clp.10.28     Document Type: Review

References (63)

1. Di Angelantonio E, Sarwar N, Perry P et al.; Emerging Risk Factors Collaboration: Major lipids, apolipoproteins, and risk of vascular disease. JAMA 302, 1993-2000 (2009).
2. Baigent C, Keech A, Kearney PM et al.; Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366, 1267-1278 (2005).
3. Graham DJ, Staffa JA, Shatin D et al.: Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292, 2585-2590 (2004).
4. Cziraky MJ, Willey VJ, McKenney JM et al.: Statin safety: an assessment using an administrative claims database. Am. J. Cardiol. 97, 61C-68C (2006).
5. Beaird SL: HMG-CoA reductase inhibitors: assessing differences in drug interactions and safety profiles. J. Am. Pharm. Assoc. 40, 637-644 (2000).
6. Liem AH, van de Woestijne AP, Roeters van Lennep HW, Zwinderman AH, van der Steeg WA, Jukema JW: ApoB/A1 and LDL-C/ HDL-C and the prediction of cardiovascular risk in statin-treated patients. Curr. Med. Res. Opin. 24, 359-364 (2008).
7. Panayiotou A, Griffin M, Georgiou N et al.: ApoB/ApoA1 ratio and subclinical atherosclerosis. Int. Angiol. 27, 74-80 (2008).
8. Foley KA, Simpson RJ Jr, Crouse JR III, Weiss TW, Markson LE, Alexander CM: Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am. J. Cardiol. 92, 79-81 (2003).
9. Phatak H, Wentworth C, Sazonov V, Burke T: Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice. Atherosclerosis 202, 225-233 (2009).
10. Kurihara Y, Douzono T, Kawakita K, Nagasaki Y: A large-scale, long-term, prospective post-marketing surveillance of pitavastatin (LIVALO Tablet): LIVALO Effectiveness and Safety (LIVES) study. Jpn Pharmacol. Ther. 36, 709-731 (2008).
11. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F: New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84, 413-428 (1999).
12. Corsini A, Maggi FM, Catapano AL: Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol. Res. 31, 9-27 (1995).
13. Shitara Y, Sugiyama Y: Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy- 3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112, 71-105 (2006).
14. Ho RH, Tirona RG, Leake BF et al.: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
15. Hsiang B, Zhu Y, Wang Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2) Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl- CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168 (1999).
16. Noé J, Portmann R, Brun ME, Funk C: Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab. Dispos. 35, 1308-1314 (2007).
17. Aoki T, Nishimura H, Nakagawa S et al.: Pharmacological profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneimittelforschung 47, 904-909 (1997).
18. Morikawa S, Umetani M, Nakagawa S et al.: Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J. Atheroscler. Thromb. 7, 138-144 (2000).
19. Saiki A, Murano T, Watanabe F, Oyama T, Miyashita Y, Shirai K: Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes. J. Atheroscler. Thromb. 12, 163-168 (2005).
20. Maejima T, Yamazaki H, Aoki T et al.: Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem. Biophys. Res. Commun. 324, 835-839 (2004).
21. Neuvonen PJ, Niemi M, Backman JT: Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565-581 (2006).
22. Fujino H, Yamada I, Kojima J, Hirano M, Matsumoto H, Yoneda M: Studies on the Metabolic Fate of NK-104, a new inhibitor of HMG-CoA reductase (5) in vitro metabolism and plasma protein binding in animals and human. Xenob. Metab. Dis. 14, 415-424 (1999).
23. Lennernäs H, Fager G: Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin. Pharmacokinet. 32, 403-425 (1997).
24. White CM: A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J. Clin. Pharmacol. 42, 963-970 (2002).
25. Yamada I, Fujino H, Shimada S, Kojima J: Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: similarities and difference in the metabolism of pitavastatin in monkeys and humans. Xenobiotica 33, 789-803 (2003).
26. Hirano M, Maeda K, Shitara Y, Sugiyama Y: Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311, 139-146 (2004).
27. Romaine SP, Balmforth AJ, Bailey KM, Hall AS: Genetics and pharmacogenomics of cardiovascular disease. Circulation 118(2), S426 (2008).
28. Ando H, Tsuruoka S, Yanagihara H et al.: Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br. J. Clin. Pharmacol. 60, 494-497 (2005).
29. Nakagawa S, Hounslow N: Pitavastatin is not subject to clinically relevant pharmacokinetic interactions when administered with CYP3A4 inhibitors in healthy volunteers. Eur. Heart J. 30(Abstract Suppl.), 958 (2009).
30. Mathew P, Cuddy T, Tracewell WG, Salazar D: An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin. Pharmacol. Ther. 75, P33 (2004).
31. Kajinami K, Mabuchi H, Saito Y: NK-104: a novel synthetic HMG-CoA reductase inhibitor. Exp. Opin. Invest. Drugs 9, 2653-2661 (2000).
32. Bizzaro N, Bagolin E, Milani L, Cereser C, Finco B: Massive rhabdomyolysis and simvastatin. Clin. Chem. 38, 1504 (1992).
33. Boyd RA, Stern RH, Stewart BH et al.: Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein- mediated secretion. J. Clin. Pharmacol. 40, 91-98 (2000).
34. Niemi M: Role of OATP transporters in the disposition of drugs. Pharmacogenomics 8, 787-802 (2007).
35. Shitara Y, Hirano M, Sato H, Sugiyama Y: Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)- mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther. 311, 228-236 (2004).
36. Hasunuma T, Masahiko N, Takashi Y et al.: The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J. Clin. Ther. Med. 19, 381-389 (2003).
37. Kalliokoski A, Niemi M: Impact of OATP transporters on pharmacokinetics. Br. J. Pharmacol. 158, 693-705 (2009).
38. Muzi M, Mankoff DA, Link JM et al.: Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J. Nucl. Med. 50, 1267-1275 (2009).
39. Arnaboldi L, Baetta R, Ferri N et al.: Inhibition of smooth muscle cell migration and proliferation by statins. Immunol. Endocr. Metab. Agents Med. Chem. 8, 122-140 (2008).
40. Saito Y, Yamada N, Teramoto T et al.: Clinical efficacy of pitavastatin, a new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung 52, 251-255 (2002).
41. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344, 1383-1389 (1994).
42. Budinski D, Arneson V, Hounslow N, Gratsiansky N: Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin. Lipidol. 4(3), 291-302 (2009).
43. Ose L, Budinski D, Hounslow N, Arneson V: Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia. Curr. Med. Res. Opin. 25(11), 2755-2764 (2009).
44. Ose L, Budinski D, Hounslow N, Arneson V: Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis (2010), doi:10.1016/j.atherosclerosis.2009.12.009 (Epub ahead of print).
45. Hiro T, Kimura T, Morimoto T et al.; JAPAN-ACS investigators: Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J. Am. Coll. Cardiol. 54, 293-302 (2009).
46. Toi T, Taguchi I, Yoneda S et al.: Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque. Comparison with atorvastatin. Circ. J. 73, 1466-1472 (2009).
47. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). NIH Publication No. 02-5215, September 2002.
48. Packard CJ, Ford I, Robertson M et al.; PROSPER Study Group: Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 112, 3058-3065 (2005).
49. Stender S, Hounslow N: Robust efficacy of pitavastatin and comparable safety to pravastatin. Atheroscler. Suppl. 10(2), P770 (2009).
50. Teramoto T, Shimano H, Yokote K, Urashima M: Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J. Atheroscler. Thromb. 16, 654-661 (2009).
51. Sviridov D, Nestel P, Watts G: Statins and metabolism of high density lipoprotein. Cardiovasc. Hematol. Agents Med. Chem. 5, 215-221 (2007).
52. Yokote K, Bujo H, Hanaoka H et al.: Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients: collaborative study on hypercholesterolemia drug intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis 201, 345-352 (2008).
53. Sasaki J, Ikeda Y, Kuribayashi T et al.: A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin. Ther. 30(6), 1089-1101 (2008).
54. Lund TM, Torsvik H, Falch D, Christophersen B, Skardal R, Gullestad L: Effect of morning versus evening intake of simvastatin on the serum cholesterol level in patients with coronary heart disease. Am. J. Cardiol. 90, 784-786 (2002).
55. Wallace A, Chinn D, Rubin G: Taking simvastatin in the morning compared with in the evening: randomised controlled trial. BMJ 327, 788 (2003).
56. Meyer Zu Schwabedissen HE, Kim RB: Hepatic OATP1B transporters and nuclear receptors PXR and CAR: interplay, regulation of drug disposition genes, and single nucleotide polymorphisms. Mol. Pharm. 6, 1644-1661 (2009).
57. Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003). (Pubitemid 37249126)
58. Link E, Parish S, Armitage A et al.; SEARCH Collaborative Group: SLCO1B1 variants and statin-induced myopathy-a genome wide study. N. Engl. J. Med. 359, 789-799 (2008).
59. Corsini A, Bellosta S: Drug-drug interaction with statins. Expert Rev. Clin. Pharmacol. 1, 105-113 (2008).
60. Bellosta S, Paoletti R, Corsini A: Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl. 1), III50-III57 (2004).
61. Poirier A, Funk C, Lavé T, Noé J: New strategies to address drug-drug interactions involving OATPs. Curr. Opin. Drug Discov. Devel. 10, 74-83 (2007).
62. WHO Cardiovascular diseases www.who.int/mediacentre/factsheets/fs317/ en/index.html (Accessed 10 December 2009).
63. BNF (British National Formulary), 57th Edition. British Medical Association and Royal Pharmaceutical Society of Great Britain, London, UK, 2009. www.bnf.org.uk/bnf/bnf/current/33422.htm (Accessed 30 June 2009).